Manulife Financial (MFC.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Manulife Financial (MFC.TO)

61.73

+0.50 (0.82%)

as of Aug 14, 2026, 8:00:00 pm Market Open.

1631 watching

Investor Insights

Aug 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) has shown a solid performance in recent quarters, buoyed by its strong presence in Asia and effective wealth management strategies. However, there are concerns regarding its valuation, as it is perceived to be somewhat overbought, trading over 2x book value with limited earnings growth expected in the near future. Despite these concerns, many experts highlight its decent dividend yield and ongoing growth potential, particularly in its Asian markets. The recent implementation of a tax on MFC products for mainland Chinese residents adds a layer of uncertainty. Overall, the sentiment among analysts is cautiously optimistic, with a call for careful monitoring of market conditions and potential entry points for investment.

Consensus

Cautious

Valuation

Fair Value

Similar

GWO

DON'T BUY

Likelihood of increasing dividends in the next year would be a surprise to him. Still not sure how regulators are going to deal with Life Insurance companies capital. His calculations show that this one has the highest upside potential in the financials but doesn't know how long it will take to get there.

Wealthica Track your Stocks in your Watch List

DON'T BUY

His least favourite in the lifecos. Operationally has been the best in North America with great growth potential in the far east. Got hung up with segregated funds in Canada and variable annuities in the US. Doesn't think they are even at half yet of hedging their portfolio. Will take a long time for investor confidence to come back.

TOP PICK

Did their last security issue to build a better financial picture for themselves. Doesn't think it's going up over the next 6 months but likes it for the long term. Price to Book is only about 1.3 times. Have growth in the US through John Hancock and in Asia.

DON'T BUY

Has Asian exposure, which he loves. However still in the penalty box for cutting dividends. Until they get out of this, there is no real rush to get into it.

DON'T BUY

Spent the last year trying to put its capital base back in “fortress” category. A couple of things are holding the company back. 1) It is most exposed of all the insurance companies to equity markets. 2) Pending changes to some of the capital requirements could put a crimp in the seg fund business.

COMMENT

7.68% Bonds maturing 2019? If you are a trader you’ve probably made the lion’s share of your capital gain and you could think about exiting in the next 3 to 6 months. If you hold on until maturity, 7.68% is a very nice yield.

DON'T BUY

Prefers Sun Life (SLF-T), which yields about 4.5%. Had some issues last year. Almost became a 2X proxy on the market because of their leveraged ETF. Since then have raised equity twice and cut the dividend. Expects Canadian insurance industry can do quite well.

BUY

Have lots of capital. There will be some volatility for the next little while. Great franchise in Canada and US and a growing franchise in Asia. Likes the prospects in 3 to 5 years from now.

BUY

(Market Call Minute.) Keep having bad news and it keeps getting in the penalty box but he thinks that things are going to come this year.

PAST TOP PICK

(A Top Pick Apr 8/09. Up 25.41%.) Still a buy.

BUY

Likes this company. Valuations looks more compelling than the banks. Good long-term hold.

TOP PICK

A contrarian pick because so many people where so badly hurt when dividend was cut and then by a share issue. On of the largest life insurance companies in the world. Thinks reserves will turn out to be too high and dividend will rise.

BUY ON WEAKNESS

Thinks we have seen the worst of the slide in the insurance sector. Maybe a little too expensive at this point.

BUY

Can see $30 in 2-3 years. Have a lot of growth in Asia. As credit concerns ease and equity markets go sideways to slightly higher their credit and capital will get better increasing their multiple.

DON'T BUY

This one is very tricky. Has been a big disappointment. Will probably stall out at around $22 and probably slide there for a while.

Showing 1,501 to 1,515 of 2,284 entries

Most Recent Experts

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Richard Orrell

RN Croft Financial Group

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Manulife Financial (MFC.TO)